Optimal LDL-C Target in High-risk Patients After PCI

Inclusion Criteria: 1. Patients underwent percutaneous coronary intervention due to acute or chronic coronary syndrome 2. Patients with ASCVD at extremely high risk 3. Patients who are able to complete the follow-up and compliant with the allocated treatment * ASCVD at extremely high risk is defined as fulfilling at least TWO of the following criteria: 1. PCI for acute myocardial infarction (AMI, including STEMI or NSTEMI) 2. Previous AMI, previous stroke, or previous intervention or surgery for peripheral vascular disease 3. Experienced cardiovascular event(s) with LDL-C≤1.8mmol/L 4. LDL-C≥4.9mmol/L 5. Diabetes 6. CKD (eGFR \< 60 ml/min/1.73m2) 7. Current smoking 8. Recurrent cardio/cerebrovascular events 9. History of premature ASCVD (\< 55 male, \< 65 female) 10. Complex PCI (fulfilling at least one of the following criteria: multivessel disease; in-stent restenosis; ≥ 3 stents implanted; total stent length ≥ 60 mm; bifurcation; left main disease; target lesions allocated in bypass graft; chronic total occlusion (≥ 3 months of occlusion)) Exclusion Criteria: 1. Age less than 18 years; 2. Unable to give informed consent or currently participating in other trials; 3. Patient who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to randomization in women of child-bearing potential according to local practice), or plans to become pregnant during treatment; 4. Concurrent medical condition with a life expectancy of less than 3 years; 5. Hemodynamic unstable; 6. Active liver disease or hepatic dysfunction (persistent unexplained ALT/AST elevations (≥ 3 × ULN)), patients with a transient increase ALT/AST due to the acute MI may be enrolled; 7. Unable to reach the LDL-C target by known intolerance or contradiction of lipid control medications; 8. LDL-C ≤ 1.4 mmol/L at baseline without any lipid control medication lowering LDL-C; 9. Known active infection or critical hematologic/endocrine dysfunction.